Abstract IA07: Defining, Optimizing, and Altering the Specificities of CRISPR-Cas Nucleases

RNA-guided CRISPR-Cas nucleases are now widely used for research and are also being rapidly developed as novel therapeutics for various human diseases. In this talk, I will discuss methods developed by our group that enable unbiased, genome-wide assessment of off-target cleavage specificities of CRISPR-Cas nucleases in human cells. I will also summarize our efforts to use protein engineering to create CRISPR-Cas nuclease variants that robustly show substantially reduced off-target effects and/or altered DNA recognition specificities. Taken together, our results have yielded reagents, methods, and insights that will be important for research applications and potential clinical translation of these programmable nucleases.Citation Format: J. Keith Joung. Defining, Optimizing, and Altering the Specificities of CRISPR-Cas Nucleases [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr IA07.
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Oral Presentations - Invited Abstracts Source Type: research